RxDoctor Payments Data

Ahmed Basheer, MD

Internal Medicine · Norfolk, MANPI 1467416958

Payments from drug & device makers

$2,356in general payments, 2019–2025

Across 125 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$406
  • Pfizer$230
  • Novo Nordisk$183
  • Boehringer Ingelheim$163
  • Esperion Therapeutics, Inc.$158
  • Lilly USA, LLC$147
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,347100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,356 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$54,778
Medicare patients
194
Services billed
1,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$37,463
OzempicSemaglutide28$37,138
JardianceEmpagliflozin22$30,136
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$26,022
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl90$12,666
SuboxoneBuprenorphine Hcl/Naloxone Hcl12$5,953
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,397
Atorvastatin Calcium247$3,252
Metoprolol Succinate114$2,243
Lisinopril206$1,962
Simvastatin127$1,713
Albuterol Sulfate HfaAlbuterol Sulfate72$1,585
Valsartan27$1,519
Olmesartan Medoxomil13$1,396
Omeprazole100$1,390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$230$37,46341 claims
Novo NordiskOzempic$183$37,13828 claims
Boehringer IngelheimJardiance$163$30,13622 claims
GSKTrelegy Ellipta$38$26,02227 claims
Indivior Inc.Suboxone$23$5,95312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Norfolk

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →